Evidence map›Paper›PMID 28726719›Full record

ArticleToxins2017

SiMa Cells for a Serotype Specific and Sensitive Cell-Based Neutralization Test for Botulinum Toxin A and E.

Nicola Bak, Shalini Rajagopal, Paul Stickings, Dorothea Sesardic

Open access · goldAbstract read
In one paragraph

Article in Toxins, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nicola BakDivision of Bacteriology, National Institute for Biological Standards and Control (NIBSC), A Centre of the Medicines and Healthcare Products Regulatory Agency, Hertfordshire EN6 3QG, UK. nicola.a.bak@gmail.com.
Shalini RajagopalDivision of Bacteriology, National Institute for Biological Standards and Control (NIBSC), A Centre of the Medicines and Healthcare Products Regulatory Agency, Hertfordshire EN6 3QG, UK. shalini.rajagopal@nibsc.org.
Paul StickingsDivision of Bacteriology, National Institute for Biological Standards and Control (NIBSC), A Centre of the Medicines and Healthcare Products Regulatory Agency, Hertfordshire EN6 3QG, UK. paul.stickings@nibsc.org.
Dorothea SesardicDivision of Bacteriology, National Institute for Biological Standards and Control (NIBSC), A Centre of the Medicines and Healthcare Products Regulatory Agency, Hertfordshire EN6 3QG, UK. thea.sesardic@nibsc.org.
National Institute for Biological Standards and Control · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Botulinum toxins (BoNTs), of which there are seven serotypes, are among the most potent neurotoxins, with serotypes A, B and E causing human botulism. Antitoxins form the first line of treatment for botulism, and functional, highly sensitive in vitro methods for toxin neutralization are needed to replace the current in vivo methods used for determination of antitoxin potency. In this preliminary proof of concept study, we report the development of a neutralization test using the neuroblastoma SiMa cell line. The assay is serotype specific for either BoNT/A or BoNT/E, which both cleave unique sequences on SNAP-25 within SiMa cells. The end point is simple immunodetection of cleaved SNAP-25 from cell lysates with antibodies detecting only the newly exposed sequence on SNAP-25. Neutralizing antibodies prevent the toxin-induced cleavage of SNAP-25. The toxin neutralization assay, with an EC50 of ~2 mIU/mL determined with a standardized reference antiserum, is more sensitive than the mouse bioassays. Relevance was demonstrated with commercial and experimental antitoxins targeting different functional domains, and of known in vivo neutralizing activities. This is the first report describing a simple, specific, in vitro cell-based assay for the detection of neutralizing antibodies against BoNT/A and BoNT/E with a sensitivity exceeding that of the mouse bioassay.

Indexed as

Antibodies, NeutralizingBotulinum ToxinsBotulinum Toxins, Type ACell DifferentiationCell Line, TumorHumansNeutralization TestsPeptidesSerogroupSynaptosomal-Associated Protein 25Antibodies, NeutralizingBotulinum ToxinsBotulinum Toxins, Type Abotulinum toxin type EPeptidesSNAP25 protein, humanSynaptosomal-Associated Protein 25BoNT/ABoNT/Ecapture ELISAcell-based assayimmunodetectionSiMa cellsSNAP-25toxin neutralization test (TNT)

Identifiers

PMID28726719
PMCPMC5535177
OpenAlexW2736511797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.